Literature DB >> 316266

Percutaneous epidural neurostimulation in modulation of paraplegic spasticity. Six case reports.

R R Richardson, L J Cerullo, D G McLone, F A Gutierrez, V Lewis.   

Abstract

Six cases of paraplegic, post-traumatic spasticity, alleviated by percutaneous epidural neurostimulation with temporary or permanent implanted neuroelectrodes from the L1 to L4 intervertebral levels are presented. Modulation of this spasticity and secondary beneficial physiological effects were achieved, including regulation of bowel regimens, production of sweating and piloerection below the level of the lesion, and morning erections. The main advantages of percutaneous epidural neurostimulation in modulating spasticity are the avoidance of destructive neurosurgical procedures, the regulation of secondary physiological and autonomic responses, the avoidance of antispasticity medications, and the reversibility of the neurostimulation procedure.

Entities:  

Mesh:

Year:  1979        PMID: 316266     DOI: 10.1007/bf01808963

Source DB:  PubMed          Journal:  Acta Neurochir (Wien)        ISSN: 0001-6268            Impact factor:   2.216


  17 in total

1.  The treatment of spastic paraplegia by selective spinal cordectomy.

Authors:  C S MACCARTY
Journal:  J Neurosurg       Date:  1954-11       Impact factor: 5.115

2.  Influence of dorsal column stimulation (DCS) on spastic movement disorders.

Authors:  U Thoden; J U Krainick; H M Strassburg; H Zimmermann
Journal:  Acta Neurochir (Wien)       Date:  1977       Impact factor: 2.216

3.  Chronic dorsal column stimulation in multiple sclerosis. Preliminary report.

Authors:  A W Cook; S P Weinstein
Journal:  N Y State J Med       Date:  1973-12-15

Review 4.  Pain mechanisms: a new theory.

Authors:  R Melzack; P D Wall
Journal:  Science       Date:  1965-11-19       Impact factor: 47.728

5.  Percutaneous epidural neurostimulation for paraplegic spasticity.

Authors:  R R Richardson; D G McLone
Journal:  Surg Neurol       Date:  1978-03

6.  Dorsal-column stimulation in the rehabilitation of patients with multiple sclerosis.

Authors:  L S Illis; A E Oygar; E M Sedgwick; M A Awadalla
Journal:  Lancet       Date:  1976-06-26       Impact factor: 79.321

7.  Modification of blood flow to the extremities by electrical stimulation of the nervous system.

Authors:  D M Dooley; M Kasprak
Journal:  South Med J       Date:  1976-10       Impact factor: 0.954

8.  Electrical stimulation in multiple sclerosis.

Authors:  A W Cook
Journal:  Hosp Pract       Date:  1976-04

9.  Deafferentation to relieve spasticity or rigidity: reasons for failure in some cases of paraplegia.

Authors:  I M Tarlov
Journal:  J Neurosurg       Date:  1966-09       Impact factor: 5.115

10.  Peripheral nerve block with phenol in the management of spasticity. Indications and complications.

Authors:  A A Khalili; H B Betts
Journal:  JAMA       Date:  1967-06-26       Impact factor: 56.272

View more
  4 in total

1.  Modification of spasticity by transcutaneous spinal cord stimulation in individuals with incomplete spinal cord injury.

Authors:  Ursula S Hofstoetter; William B McKay; Keith E Tansey; Winfried Mayr; Helmut Kern; Karen Minassian
Journal:  J Spinal Cord Med       Date:  2013-11-26       Impact factor: 1.985

Review 2.  Neuromodulation of lower limb motor control in restorative neurology.

Authors:  Karen Minassian; Ursula Hofstoetter; Keith Tansey; Winfried Mayr
Journal:  Clin Neurol Neurosurg       Date:  2012-03-29       Impact factor: 1.876

Review 3.  Neural Substrates of Transcutaneous Spinal Cord Stimulation: Neuromodulation across Multiple Segments of the Spinal Cord.

Authors:  Trevor S Barss; Behdad Parhizi; Jane Porter; Vivian K Mushahwar
Journal:  J Clin Med       Date:  2022-01-27       Impact factor: 4.241

4.  Common neural structures activated by epidural and transcutaneous lumbar spinal cord stimulation: Elicitation of posterior root-muscle reflexes.

Authors:  Ursula S Hofstoetter; Brigitta Freundl; Heinrich Binder; Karen Minassian
Journal:  PLoS One       Date:  2018-01-30       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.